Myriad Genetics Inc represents values of innovation, dedication to patients, and commitment to improving healthcare through genetic testing and personalized medicine. With a corporate philosophy centered around advancing precision medicine, Myriad Genetics is focused on developing groundbreaking molecular diagnostic tests that enable early detection and prevention of diseases such as cancer. The company aims to empower healthcare professionals and patients with reliable, actionable genetic information to make informed decisions about treatment and preventative measures. Myriad Genetics' dedication to quality, accuracy, and ethical practices makes it a trusted leader in the field of genetic testing and precision medicine.

Myriad Genetics Inc is primarily present in various countries and regions worldwide. The company has a global presence, with operations and offices in several key locations. Some of the countries and regions where Myriad Genetics Inc is primarily present include the United States, Canada, Europe (including countries like the United Kingdom, France, Germany, Italy, and Spain), Asia Pacific (including countries like Japan, China, and Australia), and Latin America. This widespread presence allows Myriad Genetics Inc to serve a wide range of customers and collaborate with medical professionals and researchers globally.

Myriad Genetics Inc has achieved several significant milestones throughout its history. One notable achievement is the development of the BRACAnalysis test, which is a groundbreaking genetic test used to identify individuals with a higher risk of developing hereditary breast and ovarian cancer. This test has revolutionized the field of genetic testing and has had a major impact on cancer prevention and treatment. Additionally, Myriad Genetics Inc has successfully expanded its portfolio to include various genetic tests for other diseases, including prostate cancer and hereditary colon cancer. The company continues to innovate and make strides in the field of genetic testing, solidifying its position as a leader in the industry.

Myriad Genetics Inc is a leading molecular diagnostics company based in the United States. Founded in 1991, the company has a rich history and has made significant contributions to the field of genetic testing and personalized medicine. Myriad Genetics Inc specializes in developing and marketing innovative genetic tests, including those for hereditary cancer and rare diseases. With a strong focus on research and development, the company has established itself as a trusted provider of genetic testing services worldwide. Myriad Genetics Inc's commitment to advancing healthcare through genetic insights has made it a prominent player in the industry.

The main competitors of Myriad Genetics Inc in the market include companies like Invitae Corporation, Illumina Inc, NeoGenomics Laboratories Inc, and Natera Inc.

Myriad Genetics Inc is primarily active in the healthcare and biotechnology industries.

The business model of Myriad Genetics Inc revolves around providing molecular diagnostic tests and genetic analysis services. As a leading molecular diagnostics company, Myriad Genetics focuses on developing and marketing innovative genetic tests for various medical conditions, including cancer and genetic disorders. With a strong emphasis on research and technology, Myriad Genetics aims to improve patient care and outcomes through personalized medicine. By offering a wide range of genetic testing services, the company strives to empower healthcare providers and individuals with valuable genetic insights, enabling more precise diagnosis, treatment decisions, and proactive healthcare management. Myriad Genetics Inc's business model primarily centers on genetic testing for various medical conditions.

De Myriad Genetics K/W is 698,98.

De Myriad Genetics KUV is 2,42.

De AlleAktien Kwaliteitsscore voor Myriad Genetics is 4/10.

De verwachte Myriad Genetics omzet is 848,49 mln. USD.

De verwachte Myriad Genetics winst is 2,93 mln. USD.

The company Myriad Genetics Inc. is a US-American company that specializes in the development and marketing of medical testing procedures and personalized medicine solutions. The business model includes three main divisions: genetic testing, molecular diagnostics, and personalized medicine. In the genetic testing division, Myriad Genetics offers a comprehensive range of genetic tests, including BRCA1 and BRCA2 tests, which are specifically designed to identify the risk of breast cancer in women and men. In addition, the company offers tests for hereditary colon and skin cancer, as well as tests for genetic disorders and hereditary types of cancer. These tests are aimed at providing doctors with a solid basis for making informed decisions, diagnosing accurately, and choosing the best treatment options for their patients. In molecular diagnostics, the company focuses on developing testing procedures specifically designed to identify the genetic basis of certain diseases. Myriad Genetics has developed a wide range of molecular tests that are used in the early detection and treatment of diseases such as breast cancer, colon cancer, and prostate cancer. Personalized medicine reflects the core idea of Myriad Genetics' business model. It involves using a patient's genetics to develop individualized treatment options. The company has developed various technologies tailored to an individual's genetic profile to enable better prediction of the effectiveness of medications and therapies. The goal is to create tailored, targeted treatment methods for patients through personalized medicine and genomic therapies. An important part of Myriad Genetics' business is collaboration with leading researchers, doctors, and medical institutions worldwide. The company has established partnerships with leading oncologists and cancer centers to promote the use of tests and personalized medicine solutions. Additionally, Myriad Genetics has a strong research department that continuously focuses on new technologies and innovative therapies for the treatment of cancer and other serious illnesses. Overall, Myriad Genetics' business model offers a comprehensive range of innovative products and services for the medical community and patients worldwide. The company continuously works to expand and improve its offerings in order to provide the best possible diagnosis and treatment options based on the individual genetic characteristics of each patient.

Myriad Genetics keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Myriad Genetics of het bedrijf keert geen dividend uit.

De ISIN van Myriad Genetics is US62855J1043.

Het WKN van Myriad Genetics is 897518.

De ticker van Myriad Genetics is MYGN.

Binnen de laatste 12 maanden betaalde Myriad Genetics een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Myriad Genetics naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Myriad Genetics is momenteel .

Myriad Genetics betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Myriad Genetics betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Myriad Genetics wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Myriad Genetics van 5-7-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 5-7-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 5-7-2024.

In het jaar 2023 heeft Myriad Genetics 0 USD aan dividenden uitgekeerd.

De dividenden van Myriad Genetics worden in USD uitgekeerd.